Biomedical subjects

B X Qu

Publications and source records attributed to B X Qu.

3 recordsLinked to original sources

PubMed2000

Applications of, and future challenges for, genetic vaccines.

Genetic vaccines have progressed significantly since the first demonstration of the technology in 1992. When Sanford and Johnston first developed the idea, two applications were envisaged. One was as a new, simple, possibly more effective, method for delivering vaccines. The other was as a new tool to explore the immune system and to discover new vaccines. As there has been relatively little emphasis on the latter, we provide three examples of the potential uses of genetic immunization for discovery/manipulation. One of these technologies may have important implications for the safety of the vaccines. Finally, we propose that the clinical application of genetic vaccines may be limited by inadequate delivery systems and propose the characteristics of an ideal system.

Animals↗

PubMed1994

A novel hypothesis: specific oncogenes and tumor suppression genes are involved in the expression of the proopiomelanocortin gene by small cell lung cancer.

The endogenous opioid beta-endorphin, a derivative of proopiomelanocortin, stimulates the growth of cloned human small cell lung carcinoma. The present hypothesis states that mutations of the retinoblastoma gene (a tumor suppressor gene) associated to the malignant transformation of bronchial cells would trigger a cascade of biomolecular events leading to 'de novo' proopiomelanocortin expression in small cell lung carcinoma.

ACTH Syndrome, Ectopic↗

PubMed1991

Angiogenesis: modulation with opioids.

1. The effect of beta-endorphin (beta-EP) and morphine sulfate (MS), in presence and absence of naloxone (NX), on chicken chorioallantoic membrane was studied as a function of blood vessel proliferation. 2. A 50% reduction in blood vessel proliferation occurred by 10 micrograms of beta-EP or by 5 micrograms of MS per egg compared to controls. 3. An individual dose, i.e. 5 micrograms of beta-EP, did not significantly inhibit blood vessel counts after initial 24 hr period of the drug application when given alone compared to inhibition occurring with combined use of NX. 4. NX (1 microgram) did not significantly reverse the angiostatic effects of MS (10 micrograms) or of beta-EP (5 micrograms). 5. The observed modulation of angiogenesis by opioids suggests involvement of beta-EP and MS in the proliferation of vascular endothelial cells. 6. This may be due to an effect of beta-EP and MS on cell-mediated immunity factors such as interferons, interleukins and prostaglandin E2.

Animals↗